Arcus Biosciences vs Vericel
Vericel reported revenue of $276 million in fiscal 2025, about the same as Arcus Biosciences' $247 million in fiscal 2025. Arcus Biosciences' revenue fell 4.3% in its latest year, and Vericel's grew 16.4%. Arcus Biosciences had an operating margin of -156.3%, against 4.0% at Vericel. Free cash flow was −$484 million at Arcus Biosciences and $25 million at Vericel.
Side by side
| Arcus Biosciences | Vericel | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $247M | $276M |
| Revenue growth | −4.3% | 16.4% |
| Revenue growth a year, last 5 years | 25.9% | 17.3% |
| Gross margin | — | 74.4% |
| Operating margin | −156.3% | 4.0% |
| Net margin | −142.9% | 6.0% |
| Free cash flow | −$484M | $25M |
| Free cash flow margin | −195.9% | 9.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.2% | 0.9% |
| Last close | $18.28 | $54.62 |
| P/E at the last close | — | 85.3× |
| Insider trades, last 12 months | sold $11.0 million | sold $8.7 million |
| Piotroski F-score | 0 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arcus BiosciencesVericel
Operating margin
Percent of revenue
Arcus BiosciencesVericel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcus BiosciencesVericel
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcus Biosciences and Vericel pages.